The basic goals of this research effort are to understand how signaling protein kinases like RSK and ERK, contribute to normal biological processes such as the regulation of cell migration, growth, proliferation and survival. Importantly, we also wish to determine how when improperly regulated, for example, following activation of a proto-oncogene product like the small G-protein Ras, these protein kinases contribute to disease phenotypes. The ultimate goal of this research is to identify potential targets for biomarker development and disease intervention. The basic aims of this proposal are to characterize RSK regulation, interacting partners and downstream effectors. We utilize various molecular, cell biological and biochemical approaches to accomplish this analysis. With this multifaceted approach, our goal is to continue to investigate how RSK signaling contributes to the biology associated with normal cell proliferation and when improperly regulated, carcinogenesis. In addition, we propose to carefully characterize ERK signaling, not only to RSK, but also to a second category of ERK effectors based on distinct interaction motifs. Again using a variety of experimental approaches, our experimental observations have proved to be extremely enlightening.
We aim to continue to investigate a unique mechanism for ERK signaling to distinct biological effectors that can provide a molecular cell fate sensing mechanism for monitoring and differentially responding to/subtle changes in ERK/RSK signal strength, location and duration. In addition, this arm of ERK signaling is intimately linked to processes contributing to cancer cell migration, survival and metastasis. Activating mutations in the Ras protbbncoprotein are observed is greater than 30% of human cancers and the~Ras:MAP kinase pathway is inappropriately activated in greater than 70% of aggressive1 human cancers such as colon, pancreatic,'lung, breast, ovary, skin, braih and others. Our current understanding of this pathway8 has already led to the development of some potential'anti-cancer therapies:that are just entering cliriicalftriails. Additional potential drug targets must be discoveredand hew drugs^toJnhibit this pathway are desperately needed/The proposed studies are leading'to the identification of new candidate drug-targetsas well aspotential targets for the development of needed bibmarkers that will be used to quickly determine if a patients'cancer has this pathway activated. Eventually, this knowledge will result in the rationale design of targeted therapies that will be both efficacious and less toxic to the patient.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA046595-26
Application #
8220932
Study Section
Special Emphasis Panel (NSS)
Program Officer
Spalholz, Barbara A
Project Start
1988-02-08
Project End
2013-06-28
Budget Start
2012-03-01
Budget End
2013-06-28
Support Year
26
Fiscal Year
2012
Total Cost
$696,598
Indirect Cost
$285,625
Name
Harvard University
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Csibi, Alfredo; Lee, Gina; Yoon, Sang-Oh et al. (2014) The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr Biol 24:2274-80
Li, Jing; Kim, Sang Gyun; Blenis, John (2014) Rapamycin: one drug, many effects. Cell Metab 19:373-9
Er, Ekrem Emrah; Mendoza, Michelle C; Mackey, Ashley M et al. (2013) AKT facilitates EGFR trafficking and degradation by phosphorylating and activating PIKfyve. Sci Signal 6:ra45
Gu, Xiaoxiao; Yu, Jane J; Ilter, Didem et al. (2013) Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis. Proc Natl Acad Sci U S A 110:14960-5
Zhang, Wenjuan; Mendoza, Michelle C; Pei, Xiaolei et al. (2012) Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling. J Biol Chem 287:11850-8
Mendoza, Michelle C; Er, E Emrah; Blenis, John (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36:320-8
Mendoza, Michelle C; Er, E Emrah; Zhang, Wenjuan et al. (2011) ERK-MAPK drives lamellipodia protrusion by activating the WAVE2 regulatory complex. Mol Cell 41:661-71
Yu, Yonghao; Yoon, Sang-Oh; Poulogiannis, George et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332:1322-6
Hoffman, Gregory R; Moerke, Nathan J; Hsia, Max et al. (2010) A high-throughput, cell-based screening method for siRNA and small molecule inhibitors of mTORC1 signaling using the In Cell Western technique. Assay Drug Dev Technol 8:186-99
Shin, Sejeong; Dimitri, Christopher A; Yoon, Sang-Oh et al. (2010) ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 38:114-27

Showing the most recent 10 out of 45 publications